Grifols SA, Barcelona (GRFS) Given Consensus Rating of “Hold” by Brokerages

Grifols SA, Barcelona (NASDAQ:GRFS) has earned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and three have assigned a buy recommendation to the company.

GRFS has been the topic of a number of recent analyst reports. Zacks Investment Research cut shares of Grifols SA, Barcelona from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Citigroup initiated coverage on shares of Grifols SA, Barcelona in a research note on Tuesday, October 31st. They set a “buy” rating on the stock. UBS cut shares of Grifols SA, Barcelona from an “outperform” rating to a “market perform” rating in a research note on Friday, November 24th. Finally, BidaskClub cut shares of Grifols SA, Barcelona from a “sell” rating to a “strong sell” rating in a research note on Saturday, December 9th.

Several hedge funds and other institutional investors have recently modified their holdings of GRFS. Comerica Bank raised its position in Grifols SA, Barcelona by 1.3% in the second quarter. Comerica Bank now owns 19,062 shares of the biotechnology company’s stock worth $389,000 after acquiring an additional 245 shares in the last quarter. Advisor Group Inc. raised its position in Grifols SA, Barcelona by 2.8% in the second quarter. Advisor Group Inc. now owns 11,471 shares of the biotechnology company’s stock worth $242,000 after acquiring an additional 309 shares in the last quarter. Neuberger Berman Group LLC raised its position in Grifols SA, Barcelona by 0.7% in the second quarter. Neuberger Berman Group LLC now owns 47,530 shares of the biotechnology company’s stock worth $1,004,000 after acquiring an additional 327 shares in the last quarter. Stifel Financial Corp raised its position in Grifols SA, Barcelona by 5.2% in the second quarter. Stifel Financial Corp now owns 12,237 shares of the biotechnology company’s stock worth $265,000 after acquiring an additional 607 shares in the last quarter. Finally, Keybank National Association OH raised its position in Grifols SA, Barcelona by 2.7% in the second quarter. Keybank National Association OH now owns 43,110 shares of the biotechnology company’s stock worth $911,000 after acquiring an additional 1,124 shares in the last quarter. Institutional investors and hedge funds own 22.50% of the company’s stock.

Shares of Grifols SA, Barcelona (NASDAQ GRFS) traded down $0.01 during midday trading on Friday, hitting $22.09. 256,400 shares of the company were exchanged, compared to its average volume of 622,288. Grifols SA, Barcelona has a fifty-two week low of $15.47 and a fifty-two week high of $24.20. The company has a current ratio of 3.17, a quick ratio of 1.39 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $14,837.74, a PE ratio of 20.12, a P/E/G ratio of 1.63 and a beta of 1.04.

TRADEMARK VIOLATION NOTICE: “Grifols SA, Barcelona (GRFS) Given Consensus Rating of “Hold” by Brokerages” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/11/grifols-sa-barcelona-grfs-given-consensus-rating-of-hold-by-brokerages.html.

Grifols SA, Barcelona Company Profile

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company specializes in providing infusion solutions, nutrition products, and medical devices for use in hospitals and clinics.

Receive News & Ratings for Grifols SA Barcelona Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA Barcelona and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply